Johannes Jacob Piete Kastelein Sells 125,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 125,000 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $26.91, for a total value of $3,363,750.00. Following the sale, the insider owned 69,302 shares of the company’s stock, valued at $1,864,916.82. The trade was a 64.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $27.40 on Thursday. The stock’s fifty day moving average is $30.47 and its two-hundred day moving average is $32.04. The firm has a market capitalization of $3.28 billion, a P/E ratio of -12.69 and a beta of 0.10. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $23.05 and a fifty-two week high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%.The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million. On average, equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

NAMS has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Jefferies Financial Group reissued a “buy” rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. BMO Capital Markets started coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 target price on the stock. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Royal Bank Of Canada cut their price target on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and an average target price of $49.73.

Institutional Investors Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Farther Finance Advisors LLC grew its stake in shares of NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after buying an additional 708 shares during the period. Wells Fargo & Company MN raised its position in shares of NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares during the period. KBC Group NV purchased a new stake in shares of NewAmsterdam Pharma during the 1st quarter valued at approximately $37,000. Navalign LLC acquired a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $46,000. Finally, AdvisorNet Financial Inc acquired a new position in NewAmsterdam Pharma in the first quarter valued at approximately $82,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.